Pricing Log in Create free account
Friday 6 November 2026 Export SPRO’s income statement to Excel — free account

Spero Therapeutics, Inc.

SPRO Healthcare Biotechnology

Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024.

Revenue
−95.6%
EPS
−433.3%
Free cash flow
+69.7%

Quarter to June 2026, against a year earlier

1.04 0.02 +1.96%
Market cap
$59.4M
P/E
7.4×
Fwd P/E
−1.8×
Dividend yield
—
F-score
5/9
Altman Z
1.04
Beneish M
−1.00
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.46
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 4 — — 1 — — — — — —
Insider Ownership 25.86%

Capital & Financial Ratios $m

Size
Market Cap 59.40
Revenue ttm 61.19
Net income ttm 7.38
Free cash flow ttm 19.58
Net debt Q (50.77)
Valuation
P/E 7.43
Forward P/E (1.83) (negative: loss-making)
Price / sales 0.99
Forward P/S Powerpack
Price / FCF 3.09
Price / book 1.36
Financial health
Current ratio Q 6.12 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (2.04)
Growth
Revenue growth Q −95.61% (below 0%: shrinking)
Operating income growth Q −306.14% (below 0%: shrinking)
EPS, this year −746.67% (below 0%: weak)
EPS, next year A +4.12%
Revenue, next year A −99.61% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +18.80% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 2.1×; over the ten years it ranged from −30.3× in 2018 to 45.3× in 2018.
P/S against its own 10 years 18.29%
10-year low 10-year high
P/B against its own 10 years 34.34%
10-year low 10-year high
EV/Sales against its own 10 years 10.92%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 76 53 40 51
Receivables 51 52 25 0
Inventory — — — —
Other — — — —
131 107 67 52
2023 2024 2025 Q'26
Payables 1 7 1 0
ST’ Debt — — — —
Other — — — —
37 49 9 8

Compound Annual Growth %

10y 5y 3y
Sales — 48.25% 7.68%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (14.87%) (8.06%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −0.25 Actual −0.13

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY24 −0.35 −0.38 Miss by 0.03
Q1 FY25 −0.55 −0.25 Beat by 0.30
Q2 FY25 −0.38 −0.03 Beat by 0.35
Q3 FY25 −0.25 −0.13 Beat by 0.12
Q3 FY26 −0.14 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.13) (0.16) — — —
’25 (0.25) (0.03) (0.13) 0.53 0.15
’24 (0.24) (0.33) (0.32) (0.38) (1.27)
’23 (0.25) (0.23) (0.06) 0.96 0.43
’22 (1.01) (0.87) (0.33) 0.55 (1.23)
’21 (0.66) (0.63) (0.70) (0.90) (2.91)
’20 (1.22) (0.85) (0.86) (0.68) (3.52)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 — — — —
’25 6 14 5 41 67
’24 9 10 13 15 48
’23 2 3 25 74 104
’22 2 2 2 47 54
’21 7 5 3 3 18
’20 2 2 4 2 9
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 16 (5) — — —
’25 (4) (18) 17 (8) (13)
’24 6 (19) 13 (23) (23)
’23 (13) (19) 16 (17) (33)
’22 (28) (23) (1) 44 (8)
’21 (15) (17) (5) (27) (64)
’20 (23) (25) (21) (16) (86)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 16 (5) — — —
’25 (4) (18) 17 (8) (13)
’24 6 (19) 13 (23) (23)
’23 (13) (19) 16 (17) (33)
’22 (28) (23) (1) 44 (8)
’21 (15) (17) (5) (27) (64)
’20 (23) (25) (21) (16) (86)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 2 4 18 9 18 54 104 48 67 61 +80.1% 0 0 — (93.8%)
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (33) (40) (42) (61) (78) (90) (46) 25 (69) 9 8 n/m
EBT margin, % (9,743.58) (2,015.46) (1,050.48) (335.73) (839.01) (491.65) (86.74) 24.48 (142.91) 13.22 0.00 +9,756.8 pt
Net income (33) (40) (42) (61) (78) (90) (46) 23 (69) 9 7 n/m
Per share, $
Per share, $ Revenue 1.07 0.77 0.25 1.00 0.42 0.59 1.42 1.97 0.89 1.19 0.00 +1.2%
Earnings (104.56) (17.82) (2.60) (3.35) (3.52) (2.91) (1.23) 0.43 (1.27) 0.15 0.14 n/m
Cash flow (92.76) (15.12) (2.48) (2.75) (3.84) (2.08) (0.21) (0.63) (0.43) (0.23) 0.34 (48.8%)
Capex (2.66) (0.01) (0.15) (0.02) (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (95.42) (15.13) (2.63) (2.77) (3.84) (2.08) (0.21) (0.63) (0.43) (0.23) 0.34 (48.9%)
Book value 20.37 32.84 7.24 4.11 5.90 2.86 2.02 2.03 0.85 1.05 0.76 (28.0%)
Shares, m 0 3 16 18 22 31 38 53 54 56 57 +78.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.53 0.00 15.53 7.43 1.9
P/S 0.00 15.87 24.81 9.63 46.52 27.09 1.22 0.77 1.16 1.95 0.99 12.9
P/B 0.00 0.37 0.85 2.34 3.29 5.60 0.86 0.75 1.21 2.21 1.36 1.7
EV/Sales 0.00 (28.24) (4.29) 5.11 32.92 19.08 (0.82) 0.04 0.06 1.35 0.16 2.5
EV/FCF 0.61 1.39 0.40 (1.84) (3.57) (5.41) 5.63 (0.11) (0.12) (7.13) 0.49 (1.0)
Cash, $m
Cash, $m Operating cash flow (29) (39) (40) (50) (86) (64) (8) (33) (23) (13) 20 (8.8%)
Capex (1) 0 (2) 0 0 0 — — — — 0 n/m
Free cash flow (30) (39) (42) (50) (86) (64) (8) (33) (23) (13) 20 (9.1%)
Balance, $m
Balance, $m Working capital 5 84 112 69 125 139 92 94 58 58 43 +31.5%
Net debt (10) (87) (115) (82) (127) (146) (109) (76) (53) (40) (51) +16.3%
Shareholders’ equity 6 85 116 75 132 88 76 107 46 59 44 +28.1%
Returns, %
Returns, % ROA (434.62) (85.96) (37.45) (51.83) (60.74) (55.32) (31.37) 14.85 (46.81) 9.55 12.85 +444.2 pt
ROIC 0.00 0.00 (6,493.63) 0.00 (963.10) 0.00 0.00 43.93 0.00 21.04 0.00 +21.0 pt
ROE (169.30) (258.18) (41.49) (63.99) (76.31) (81.48) (56.53) 24.95 (89.62) 16.31 19.17 +185.6 pt
People
People Employees 29 35 41 57 89 146 35 46 32 25 — (1.6%)
Revenue/emp, $m 0.01 0.06 0.10 0.32 0.10 0.13 1.53 2.26 1.50 2.67 — +83.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Spero Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CING Cingulate Inc. $61.7M — (loss-making) — — n/m −24.28% (below 0%: shrinking) 0.00% 0.00% Compare
FBIO Fortress Biotech, Inc. $61.4M 0.6× 0.8× +14.04% (above 0%: growing) n/m −115.37% (below 0%: shrinking) 67.18% (53.46%) Compare
TENX Tenax Therapeutics, Inc. $61.0M — (loss-making) — −77.98% (below 0%: shrinking) n/m −125.93% (below 0%: shrinking) 0.00% 0.00% Compare
CGTX Cognition Therapeutics, Inc. $60.4M — (loss-making) — — n/m +45.35% (above 0%: growing) 0.00% 0.00% Compare
SPRO Spero Therapeutics, Inc. $59.4M 7.4× — (loss-making) −95.61% (below 0%: shrinking) n/m +69.73% (above 0%: growing) 100.00% 0.00%
CRDF Cardiff Oncology, Inc. $58.8M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%) Compare
GOSS Gossamer Bio, Inc. $57.6M — (loss-making) — (loss-making) −19.59% (below 0%: shrinking) n/m +16.32% (above 0%: growing) 100.00% (282.25%) Compare
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
XBIT XBiotech Inc. $57.0M — (loss-making) — (loss-making) −93.33% (below 0%: shrinking) n/m +25.25% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $59.6M — — −19.59% — −32.82% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 2.90%
GSK plc 15.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Spero Therapeutics, Inc. (SPRO) Latest News

26 Oct

Impact 4 · · GlobeNewswire

21 Oct

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

2 Oct

Impact 3 · · GlobeNewswire

19 Aug

Impact 4 · · The Motley Fool transcript

13 Aug

Impact 5 · transcript
Impact 3 · · Moby transcript

12 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

27 Jul

Impact 3 ·

15 Jul

Impact 5 · · hospitalmanagement.net
Impact 4 · · pharmaceutical-technology.com

14 Jul

Impact 4 · · InvestorsHub
Impact 4 ·
Impact 4 ·
Impact 4 ·

21 Jun

Impact 4 ·

18 Jun

Impact 5 · · InvestorsHub

17 Jun

Impact 5 ·
Impact 4 ·

13 May

Impact 3 · · GlobeNewswire

26 Mar

Impact 3 · · GlobeNewswire

5 Feb

Impact 3 · · Simply Wall St.

7 Jan

Impact 4 · · Simply Wall St.

19 Dec

Impact 4 · · GlobeNewswire

15 Dec

Impact 4 · · Simply Wall St.

13 Nov

Impact 3 · · GlobeNewswire

4 Nov

Impact 4 · · Simply Wall St.

14 Oct

Impact 4 · · GlobeNewswire

10 Oct

Impact 4 · · Zacks
stockrow.com/SPRO · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com